Brokerages forecast that Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) will announce earnings of ($0.67) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Bellerophon Therapeutics’ earnings. The highest EPS estimate is ($0.61) and the lowest is ($0.74). Bellerophon Therapeutics reported earnings per share of ($0.84) during the same quarter last year, which would suggest a positive year-over-year growth rate of 20.2%. The company is expected to issue its next quarterly earnings report on Thursday, November 4th.
According to Zacks, analysts expect that Bellerophon Therapeutics will report full-year earnings of ($2.46) per share for the current year, with EPS estimates ranging from ($2.95) to ($2.15). For the next year, analysts anticipate that the business will report earnings of ($2.51) per share, with EPS estimates ranging from ($2.80) to ($2.20). Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Bellerophon Therapeutics.
Bellerophon Therapeutics (NASDAQ:BLPH) last announced its quarterly earnings results on Thursday, August 5th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.26.
Shares of BLPH traded down $0.09 during trading hours on Wednesday, reaching $3.84. 157 shares of the company traded hands, compared to its average volume of 107,544. The company’s fifty day moving average price is $4.17 and its two-hundred day moving average price is $4.66. The company has a market capitalization of $36.50 million, a price-to-earnings ratio of -1.50 and a beta of -0.53. Bellerophon Therapeutics has a 12 month low of $3.66 and a 12 month high of $11.01.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its position in Bellerophon Therapeutics by 261.4% during the fourth quarter. JPMorgan Chase & Co. now owns 10,701 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 7,740 shares during the period. BlackRock Inc. boosted its position in shares of Bellerophon Therapeutics by 2.3% in the first quarter. BlackRock Inc. now owns 321,782 shares of the biotechnology company’s stock worth $1,670,000 after purchasing an additional 7,165 shares during the period. GSA Capital Partners LLP boosted its position in shares of Bellerophon Therapeutics by 6.7% in the first quarter. GSA Capital Partners LLP now owns 63,566 shares of the biotechnology company’s stock worth $330,000 after purchasing an additional 3,977 shares during the period. Element Capital Management LLC bought a new position in shares of Bellerophon Therapeutics in the first quarter worth approximately $60,000. Finally, Renaissance Technologies LLC boosted its position in shares of Bellerophon Therapeutics by 9.1% in the first quarter. Renaissance Technologies LLC now owns 233,799 shares of the biotechnology company’s stock worth $1,213,000 after purchasing an additional 19,500 shares during the period. 13.62% of the stock is owned by hedge funds and other institutional investors.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline include PH-ILD, PH-COPD and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.
Featured Story: VIX – Volatility Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.